However, the European Group on Tumor Markers currently discourages the use of IHC- or PCR-based uPA detection for clinical purposes22 so as long as the uPA analysis in fixed tissues has not been clinically validated for survival prediction, the biomarker remains a rarely chosen tool to identify high-risk non-metastatic patients in need of chemotherapy17. The gene discussed is PLAU; the disease is neoplasm.